摘要
目的了解Ⅱ型糖尿病患者血清甲脑啡肽（MEK）降解活性。方法采用体外MEK酶解，反相高效波相色谱（HPLC）定量测定MEK含量。结果①NIDDM患者血中降解MEK活性（2625．94±886．64nmol/L）较正常对照组（2164.82±769.73nmol/L）明显增高（P＜0．05）。②在5例NIDDM病例中，降糖药物治疗前后比较，治疗后4例MEK降解活性下降，1例增高。③部分血清进行MEK降解活性特异性了解，可见其降解活性可完全被bestatin抑制，而captopril对其无作用。④病人血糖水平与血中MEK降解活性正相关（r＝0．4089,P＜0．05）；而正常对照组两者显示无关（r=-0．0585，P＞0．1）。结论NIDDM患者血中NEK降解活性较正常人群增高。
Objective To reaserch serum degradative enzymes activities to MEX in patient with NIDDM. Mehtods Reversd phase HPLC wrer used for determinatiog MEK concentration in vitro. Results ①The serum degradative enzymesactivties to MEK were significantly increased in NIDDM group(2625. 94± 866.64nmol/L ) than that in normal control (2164.82± 769.73 nmol/L), P <0.05. ②In 5 cases with NIDDM, the serum degradative enzymes activities to MEK were compared before and after treatment .It was found that serum MEEK degradative enzymes decreased in 4 cases, while increased in l case after treatment .③The serum MEK degradative enzymes activities were entirely inhibited by bestatin, but not by captopril.④A significantly positive correlation was found between the fasting plasma glucose concentration and the MEX degradative enzymes activeties in NIDDM patient group(r=0.4089, P < 0.05); but no associated between that in normal control (r = - 0.058 5, P > 0. 1). Conclusion Serum MEK degradative enzymes activities were increased in NIDDM patients
出处
《广东医学》
CAS
CSCD
1999年第1期13-14,共2页
Guangdong Medical Journal
关键词
甲脑啡肽
Ⅱ型
糖尿病
降解活性
Met-enkephalin NIDDM Met-enkephalin degradative activities
